Top Canadian, Indian institutions form $30M partnership
Eradication of disease and improved water quality top priorities.
Award Winning NGDI Members, Robert EW Hancock and Brett Finlay
NGDI Congratulates it’s award winning members.
iCo Therapeutics Oral AmpB Presented at AAPS
Company also announcing a new patent position for lead NGDI project.
Funding for neglected global diseases research at UBC exceeds $20M
UBC press release and article from Vancouver Sun published last week.
2012 AAPS Pharmaceuticals NGDI Travelships Awarded
NGDI-UBC is pleased to announce three $750 travelships for students presenting papers at AAPS October Annual Meeting.
Neglected Populations: Safeguarding the Health of Street-Involved Children in Ghana
Jo-Ann Osei-Twum and Kishor Wasan, authors of new Global Health Commentary in the Journal of Pharmaceutical Sciences.
NGDI Member Funding of over $4,000,000
NGDI congratulates our members for this outstanding work.
Lead NGDI Project Oral Amphotericin B Receives $1.1 million
UBC drug formulation receives funding for clinical development as HIV treatment
Dr. Robert Hancock`s Peptide Work May Lead to New Treatment Approach to Malaria
Anti-inflammatory agents developed by NGDI Co-Founder Robert Hancock, used in combination with anti-malarial drugs, have been shown to boost survival rates of severe malaria.
NGDI-UBC article in the International Pharmacy Journal
An article on NGDI and the work it has been doing at UBC was published in the International Pharmacy Journal.